Brian Rosenberger - Sep 12, 2023 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc. (ZYNE)

Role
VP, Commercial & Business Dev.
Signature
/s/ Albert P. Parker, Attorney-in-Fact
Stock symbol
ZYNE
Transactions as of
Sep 12, 2023
Transactions value $
-$8,499
Form type
4
Date filed
9/14/2023, 04:14 PM
Previous filing
Feb 9, 2023
Next filing
Oct 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYNE Common Stock Award +22.2K +9.5% 256K Sep 12, 2023 Direct F1
transaction ZYNE Common Stock Sale -$8.5K -6.41K -2.5% $1.33 250K Sep 13, 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On September 12, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 22,200 performance-based restricted stock awards granted in a prior year.
F2 This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.